🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. berotralstat

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule active

    2 trials

  2. bevacizumab

    Outlook Therapeutics NL B. V.

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

  3. bevacizumab

    Outlook Therapeutics NL B. V.

    Age-related Macular Degeneration

    phase 3 mab active

    4 trials

  4. bimekizumab

    Lacuna Pharma Pty Ltd

    Active juvenile idiopathic arthritis subtypes enthesitis-related arthritis (including juvenile-onset ankylosing spondylitis) and juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  5. blisibimod

    Santhera Pharmaceuticals (Deutschland) GmbH

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  6. camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  7. casirivimab+imdevimab combination therapy

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule terminated

    1 trial

  8. centrally blinded product containing all the same manufactured ingredients and excipients as the DM199 formulation, except for the active pharmaceutical ingredient (API).

    DiaMedica Therapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  9. chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Limited Stage Small Cell Lung Cancer

    phase 3 other active

    1 trial

  10. cisplatin

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 3 small molecule completed

    1 trial

  11. cisplatin i.p.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Epithelial Carcinoma, Ovarian

    phase 3 small molecule active

    1 trial

  12. clopidogrel and aspirin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Atherosclerosis

    phase 3 small molecule active

    1 trial

  13. cyclophosphamide

    Partner Therapeutics Limited

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  14. dabigatran dose 1

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  15. dabigatran etexilate

    Boehringer Ingelheim

    Venous Thromboembolism

    phase 3 small molecule completed

    1 trial

  16. daclatasvir

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  17. decitabine

    The First People's Hospital of Lianyungang

    Acute Myelocytic Leukemia

    phase 3 small molecule active

    1 trial

  18. decitabine

    The First People's Hospital of Lianyungang

    Poor Graft Function

    phase 3 small molecule active

    1 trial

  19. dehydroepiandrosterone

    Ultragenyx UK Limited

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    3 trials

  20. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    7 trials

  21. deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  22. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  23. dichlorphenamide

    Ultragenyx UK Limited

    Paralysis, Hyperkalemic Periodic

    phase 3 small molecule completed

    1 trial

  24. didroxyprogesterone

    The First People's Hospital of Lianyungang

    Pregnancy Rate

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources